Recent Conferences
October 14, 2010
Fall Forum
July 8, 2010
Summer Forum
April 15, 2010
Spring Forum
October 14, 2009
Accelerating High-Value Healthcare
September 16, 2009
Next Steps Toward a Robust Comparative Effectiveness Research Enterprise
July 20, 2009
Establishing a National Health Insurance Exchange
June 11, 2009
Federal Strategies for Promoting Affordable Biologics: Follow-On Biologic Competition
April 29, 2009
Implementing Bundled Payments for Health Care Services
November 24, 2008
Medicare Delivery System Reform
October 2, 2008
Specialty Pharmaceuticals: Policy Solutions for Encouraging Access and Affordability
July 16, 2008
Managing Specialty Pharmaceuticals
June 4, 2008
"Road Testing" Electronic Medical Records
April 30, 2008
Innovation Workgroup
April 10, 2008
Payment and Delivery System Reform
November 29, 2007
Comparative Effectiveness Congressional Briefing
November 27, 2007
Overview of Cost Management Strategies
October 24, 2007
Coverage With Evidence Development
October 2, 2007
Value-Based Payment for Medical Technologies
September 18, 2007
Personalized Medicine Conference
July 25, 2007
Comparative Effectiveness: Stakeholder Perspectives
April 11, 2007
Post Marketing Surveillance
February 14, 2007
Comparative Effectiveness Research: Congressional Briefing
November 30, 2006
Comparative Effectiveness Forum
October 12, 2006
Coverage Policy in an Era of Personalized Medicine
July 13, 2006
Pharmaceutical Benefit Management
May 1, 2006
Methodology Standards
April 4, 2006
Technology Assessment
October 3, 2005
Promoting Appropriate Utilization
April 1, 2005
Evidence-Based Health Care System
July 16, 2004
Correcting Underuse in Health Care
June 11, 2009
Federal Strategies for Promoting Affordable Biologics: Follow-On Biologic Competition
One proposed strategy for improving the affordability of biologics is creating an FDA approval pathway for “biosimilars.” This is the subject of legislation recently filed by Energy and Commerce Chairman Waxman and a soon to be released Federal Trade Commission report.
This Forum will examine unique science and regulatory questions concerning biosimilars’ interchangeability, potential impact on both market competition and reimbursement strategies, and broad policy consideration concerning the potential economic implications for patients, payers, and product manufacturers.
Presentations:
Follow-on Protein Products: Comparability and Risk
William M. Egan, Ph.D., Vice President, PharmaNet Consulting
Data Protection for Biologics: Balancing Innovation Incentives and Cost Savings
Henry G. Grabowski Ph.D., Professor, Duke University
Follow-on Biologic Drug Competition: A Report by the Federal Trade Commission
Pamela Jones Harbour, Commissioner
